Latest Conference Articles

There are still many aspects of sleep health that need to be understood, especially in relation to the COVID-19 pandemic.

Investigators contribute more detailed understanding of the association between sleeping disorder and cardiovascular event risks.

Patients with diabetic retinopathy showed significantly higher updated first-year HbA1c and at follow-up compared to those free from DR.

Sleep issues are prevalent among children with autism or ADHD and both these common disorders are increasing. Any provider working with children is most likely going to encounter patients struggling with sleep.

A higher percentage of participants in the pooled dulaglutide group had a glycated hemoglobin level of <7.0% than the placebo group at week 26 of the AWARD-PEDS trial.

Late-breaking data from SLEEP 2022 show there may be biological plausibility for cardiovascular risks in excessively sleepy individuals.

The study from SLEEP 2022 is the first to explore directionality of sleep-stress relationships in a sample of perinatal women.

Even after controlling for differences in age and BMI, investigators observe a greater burden of sleep health on those who had severe COVID-19 versus the general population.

The late-breaking data show SGLT2is are underutilized in patients with heart failure with or without type 2 diabetes despite guideline recommendations.

Today in a late-breaking abstract from SLEEP 2022, data showed the reduction of slow wave activity in unmedicated adolescents with depression.

Investigators observe an increased risk of dream enactment among specific subgroups of veterans with trauma.

Dr. Aric Prather and his team at UCSF are running a large study that began in March 2021 which follows healthy individuals through the COVID-19 vaccination and booster process.

The findings are in contrast to previous research that suggests an inverse relationship between moderate-to-vigorous physical activity and HbA1c, TIR.

Data from SLEEP 2022 suggests children with OSA may have faced worse psychosocial burden during the pandemic.

The study objective was to determine if actigraphy could serve as a complementary clinical tool for sleep evaluation in patients with rheumatoid arthritis.

The findings presented at SLEEP 2022 differ from previous studies that evaluated the objective-subjective sleep patterns of this population.

A new study from SLEEP 2022 showed asthmatic children have a 10 times greater risk of the condition, and are twice as likely to have a history of snoring.

New SUNRISE 2 data show a subjective, dose-dependent, and disease severity-dependent benefit with the insomnia therapy.

Sleep expert Aric Prather, PhD, presented a discussion at SLEEP 2022 that focused on how the immune system and sleep are related to the "ongoing and protracted" impact of the COVID-19 pandemic.

The FDA-approved sleep agent was associated with ≥5% weight loss in more than one-quarter of patients in a phase 3 trial.

The mean time below range following exercise sessions was significantly lower with IGlar U300 compared to IDEG at the 100% dose.

The late-breaking findings at ADA 2022 suggest patients were more often prescribed oral semaglutide by primary care physicians than endocrinologists.

Prof. Hertzel Gerstein discusses new ELIXA biomarker findings from ADA 2022.

However, the post-hoc analysis found a greater variability in HbA1c levels was associated with increased risk of cardiorenal outcomes.

The diabetologist and professor discusses new findings from the ReTUNE trial, which disparage the utility of BMI in defining diabetes risk and remission opportunity.

New post hoc data from the STEP 1 and 4 trials show an approximate 60% risk reduction of type 2 diabetes over 10 years versus placebo.

In recent years more and more biologics have come on the market for the treatment of IBD.

The phase 3 research being presented at the EULAR 2022 conference evaluated the efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis.

A Montefiore residency director explains the impact of engaging with communities to improve mental health care capability.

A greater reduction in UACR was observed with finerenone in patients taking GLP-1RA at baseline.